Mouse monoclonal antibody to h
uman MBNL1 protein【1D11]: IgG/Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG/Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG- 询价
- Biosensis
- 澳大利亚
- M-913-100-E
- 2025年07月10日
- Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 小鼠
- Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant human MBNL1 protein【1-343], with a GST tag.
- 亚型：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 形态：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 保存条件：
厂家建议常温运输。自购买之日起，保持冻干粉状态于-20℃，有效期为12个月。抗体溶解之后，建议分装保存于-20℃，请避免反复冻融。
- 克隆性：
单克隆
- 标记物：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 适应物种：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 保质期：
根据订购时间与产品批次判定，欢迎联系艾美捷咨询确认
- 抗原来源：
小鼠
- 目录编号：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 级别：
一抗
- 库存：
小鼠来源毒性抗体：人MBNL1蛋白【1D11】：IgG
- 供应商：
艾美捷
- 宿主：
小鼠
- 应用范围：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 浓度：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 靶点：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 抗体英文名：
Mouse monoclonal antibody to human MBNL1 protein【1D11]: IgG
- 抗体名：
小鼠来源毒性抗体：人MBNL1蛋白【1D11】：IgG
- 规格：
100ug
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ANTIBODY BINDING TO PROTEIN A AND PROTEIN G
A Protein G Human IgG1 ++++ ++++ Human IgG2 ++++ ++++ Human IgG3 - ++++ Human IgG4 ++++ ++++ Mouse IgG1 + ++++ Mouse IgG
Isolation of Human Monoclonal Antibodies Using Guided Selection with Mouse Monoclonal Antibodies
Repertoires of antibody (Ab) V genes derived from nonimmunized human donors (1 ) or made synthetically (2 3 ) have been cloned for display on filamentous bacteriophage as either scFvs or Fabs fused to the minor phage coat protein (pIII
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
